Gujarat Themis Biosyn Limited has informed the Exchange regarding Cessation of Mr as Non- Executive Independent Director of the company w.e.f. September 20, 2025.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Themis Biosyn's board approved unaudited Q1 FY26 results (quarter ended June 30, 2025) with net profit of ₹906.16 lakhs, down about 31% from ₹1,323.62 lakhs in Q1 FY25, on total income of ₹3,614.72 lakhs. EPS for the quarter stood at ₹0.83 versus ₹1.21 a year ago. The board fixed September 5, 2025 as the record date for the FY25 dividend. Mr. Siddharth Kusumgar, Independent Director, will step down on September 20, 2025 after completing his second consecutive term, and Mr. Nihar Parikh (DIN: 02475787), a venture capitalist and former CEO of ZCL Chemicals, has been appointed as Additional Non-Executive Independent Director in his place from August 1, 2025. The board also confirmed it has dropped the previously announced merger with Themis Medicare Limited and will instead focus on its core fermentation-based pharma intermediates business.
For shareholders, the weak Q1 earnings and the abandonment of the Themis Medicare merger are mildly negative signals, but the recently commissioned new API plant and the focus on the core fermentation business may support longer-term growth. The dividend record date suggests an upcoming payout, while the director change is a routine succession and unlikely to impact the stock materially.